NCT05896527

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 229 (actual)
• Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	DC-806	DC-806 was supplied as tablets to be administered orally.
OTHER	Placebo	Matching placebo was supplied as tablets to be administered orally.

Timeline

• Start date: 2023-05-02
• Primary completion: 2024-03-25
• Completion: 2024-03-25
• First posted: 2023-06-09
• Last updated: 2025-04-04
• Results posted: 2025-04-04

Locations

56 sites across 8 countries: United States, Canada, Czechia, Germany, Hungary, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study